NZ571665A - Compositions and methods for treatment of radiation exposure utilising cross-linked muramyl dipeptide microparticles - Google Patents

Compositions and methods for treatment of radiation exposure utilising cross-linked muramyl dipeptide microparticles

Info

Publication number
NZ571665A
NZ571665A NZ571665A NZ57166508A NZ571665A NZ 571665 A NZ571665 A NZ 571665A NZ 571665 A NZ571665 A NZ 571665A NZ 57166508 A NZ57166508 A NZ 57166508A NZ 571665 A NZ571665 A NZ 571665A
Authority
NZ
New Zealand
Prior art keywords
radiation
mdp
microparticle
use according
medicament
Prior art date
Application number
NZ571665A
Other languages
English (en)
Inventor
Frank B Gelder
Gillian Alison Webster
Original Assignee
Innate Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Therapeutics Ltd filed Critical Innate Therapeutics Ltd
Priority to NZ571665A priority Critical patent/NZ571665A/en
Priority to CN2009801387748A priority patent/CN102170898A/zh
Priority to ES09818038T priority patent/ES2435438T3/es
Priority to PCT/NZ2009/000207 priority patent/WO2010039048A1/en
Priority to BRPI0913783A priority patent/BRPI0913783A2/pt
Priority to JP2011530016A priority patent/JP6053283B2/ja
Priority to CA2738622A priority patent/CA2738622C/en
Priority to AU2009300442A priority patent/AU2009300442B2/en
Priority to US13/121,796 priority patent/US10232010B2/en
Priority to EP09818038.3A priority patent/EP2349311B1/en
Publication of NZ571665A publication Critical patent/NZ571665A/en
Priority to JP2015160135A priority patent/JP2016026157A/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1094—Shielding, protecting against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
NZ571665A 2008-09-30 2008-09-30 Compositions and methods for treatment of radiation exposure utilising cross-linked muramyl dipeptide microparticles NZ571665A (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
NZ571665A NZ571665A (en) 2008-09-30 2008-09-30 Compositions and methods for treatment of radiation exposure utilising cross-linked muramyl dipeptide microparticles
JP2011530016A JP6053283B2 (ja) 2008-09-30 2009-09-30 放射線被曝の処置のための組成物および方法
ES09818038T ES2435438T3 (es) 2008-09-30 2009-09-30 Composiciones y métodos para el tratamiento de la exposición a la radiación
PCT/NZ2009/000207 WO2010039048A1 (en) 2008-09-30 2009-09-30 Compositions and methods for treatment of radiation exposure
BRPI0913783A BRPI0913783A2 (pt) 2008-09-30 2009-09-30 método de tratamento, profilático ou terapêutico de exposição à radiação ou envenenamento por radiação, método de aceleração de restauração de medula óssea, método de aceleração da mielorrestauração, método de estimulação da liberação de citocinas, método de indução de trombocitose e micropartícula-mdp ou uma composição
CN2009801387748A CN102170898A (zh) 2008-09-30 2009-09-30 用于辐射暴露治疗的组合物和方法
CA2738622A CA2738622C (en) 2008-09-30 2009-09-30 Compositions and methods for treatment of radiation exposure
AU2009300442A AU2009300442B2 (en) 2008-09-30 2009-09-30 Compositions and methods for treatment of radiation exposure
US13/121,796 US10232010B2 (en) 2008-09-30 2009-09-30 Compositions and methods for treatment of radiation exposure
EP09818038.3A EP2349311B1 (en) 2008-09-30 2009-09-30 Compositions and methods for treatment of radiation exposure
JP2015160135A JP2016026157A (ja) 2008-09-30 2015-08-14 放射線被曝の処置のための組成物および方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NZ571665A NZ571665A (en) 2008-09-30 2008-09-30 Compositions and methods for treatment of radiation exposure utilising cross-linked muramyl dipeptide microparticles

Publications (1)

Publication Number Publication Date
NZ571665A true NZ571665A (en) 2011-01-28

Family

ID=42073685

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ571665A NZ571665A (en) 2008-09-30 2008-09-30 Compositions and methods for treatment of radiation exposure utilising cross-linked muramyl dipeptide microparticles

Country Status (10)

Country Link
US (1) US10232010B2 (enExample)
EP (1) EP2349311B1 (enExample)
JP (2) JP6053283B2 (enExample)
CN (1) CN102170898A (enExample)
AU (1) AU2009300442B2 (enExample)
BR (1) BRPI0913783A2 (enExample)
CA (1) CA2738622C (enExample)
ES (1) ES2435438T3 (enExample)
NZ (1) NZ571665A (enExample)
WO (1) WO2010039048A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2926507A1 (en) * 2015-10-06 2017-04-06 Innate Immunotherapeutics Limited Compositions and methods for protection and/or repair of the nervous system
WO2017059486A1 (en) * 2015-10-06 2017-04-13 Innate Immunotherapeutics Limited Compositions and methods for the treatment of epilepsy
WO2017070731A1 (en) * 2015-10-28 2017-05-04 Innate Immunotherapeutics Limited Compositions and methods for the treatment of alzheimer's disease
CN108273038B (zh) * 2018-03-16 2019-03-19 中国人民解放军军事科学院军事医学研究院 防治肠型放射病的药物组合物
CN111060697A (zh) * 2019-02-24 2020-04-24 中国疾病预防控制中心辐射防护与核安全医学所 一种利用hmgb1的小肠放射性损伤标记方法
WO2022150763A1 (en) * 2021-01-11 2022-07-14 The George Washington University Nanoparticle-mediated immune cell manufacture and uses thereof
TWI843989B (zh) 2021-02-19 2024-06-01 美商美威高能離子醫療系統公司 用於粒子治療系統之支架

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4815446A (en) * 1985-05-09 1989-03-28 Alpha Therapeutic Corporation Process for treating metastasis of cancerous tumors
AU686660B2 (en) * 1993-08-11 1998-02-12 Jenner Technologies Prostatic cancer vaccine
GB9320820D0 (en) * 1993-10-08 1993-12-01 Biokine Tech Ltd Compounds for medicinal use
CA2268372C (en) * 1996-10-10 2012-11-27 Probe International Compositions and methods for treating viral infections
CA2315115C (en) 1998-10-23 2007-03-20 Polyheal Ltd. Compositions of microspheres for wound healing
JP5662309B2 (ja) * 2008-04-01 2015-01-28 イネイト・イムノセラピューティクス・リミテッド 腫瘍性疾患を治療するための組成物および方法

Also Published As

Publication number Publication date
US20110236346A1 (en) 2011-09-29
EP2349311A4 (en) 2012-07-04
CA2738622A1 (en) 2010-04-08
EP2349311B1 (en) 2013-08-21
CN102170898A (zh) 2011-08-31
BRPI0913783A2 (pt) 2016-11-01
EP2349311A1 (en) 2011-08-03
JP2012504161A (ja) 2012-02-16
CA2738622C (en) 2016-10-18
ES2435438T3 (es) 2013-12-19
JP6053283B2 (ja) 2016-12-27
JP2016026157A (ja) 2016-02-12
AU2009300442A1 (en) 2010-04-08
WO2010039048A1 (en) 2010-04-08
US10232010B2 (en) 2019-03-19
AU2009300442B2 (en) 2014-03-13

Similar Documents

Publication Publication Date Title
CA2738622C (en) Compositions and methods for treatment of radiation exposure
US20220105186A1 (en) Compositions Containing Nucleosides and Manganese and Their Uses
CN107669692A (zh) Mpla在制备电离辐射致肠道损伤防治药物中的应用
Liu et al. Radioprotective effect of orally administered beta-d-glucan derived from Saccharomyces cerevisiae
Gupta et al. Amelioration of radiation-induced hematological and biochemical alterations by Alstonia scholaris (a medicinal plant) extract
JP5553306B2 (ja) 放射線障害防護剤
WO2007150049A2 (en) Lactoferrin as a radioprotective agent
Salem et al. Anticancer activity of Egyptian marine alga Ulva rigida
CN119564713A (zh) 松果菊苷在制备预防或治疗辐射损伤的药物中的用途
AU2016222458B2 (en) Compositions containing Nucleosides and Manganese and their Uses
CN118021939A (zh) Bmp4蛋白或其衍生物在制备药物中的用途
AU2014200523B2 (en) Compositions containing Nucleosides and Manganese and their Uses
Ragheb Radiation hormesis
Singh et al. Radioprotectants: Basic concepts, current status and future directions
CN111450104A (zh) 维生素d在防治辐射所致肠损伤中的用途
CN108904479A (zh) 二烯丙基一硫在制备辐射引起白细胞减少的药物中的应用

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 30 SEP 2016 BY SHELSTON IP

Effective date: 20130923

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 SEP 2017 BY SHELSTON IP PTY LTD

Effective date: 20160926

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 SEP 2018 BY SHELSTON IP PTY LTD

Effective date: 20170926

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 SEP 2019 BY SHELSTON IP PTY LTD

Effective date: 20180716

LAPS Patent lapsed